Rheumatoid arthritis is a systemic autoimmune rheumatic disorder of unknown etiology.
It is the most common form of inflammatory arthritis.
Patient usually complains of joint pain and/or swelling with morning stiffness that lasts for more than an hour.
Goals of treatment are clinical & radiological remission of disease and to reduce functional limitations & permanent joint damage.
Biologic disease-modifying antirheumatic drugs such as tocilizumab and abatacept produce better treatment response in rheumatoid arthritis compared with tumour necrosis factor inhibitors (TNFi) when used in the first- or second-line setting and despite channelling of more severe patients to non-TNFi biologics, according to a study.
B-cell depletion therapy with rituximab leads to a significant delay in the onset of rheumatoid arthritis (RA) in individuals at high risk of developing the disease, demonstrating the pathogenetic role of B cells in the earliest prearthritis stage of autoantibody positive RA, according to data from the PRAIRI study.
Sexual dysfunction appears to be common among female patients with rheumatoid arthritis (RA) and affects all subdomains of sexual function, reports a study. However, female sexual dysfunction (FSD) is most likely undervalued in daily clinical practice.
Bone erosions occur commonly in elderly-onset rheumatoid arthritis (EORA), and clinical remission at 1 or 2 years does not appear to protect against the loss of bone in anticitrullinated protein antibody (ACPA)-positive EORA patients, according to a study.
New drug applications approved by US FDA as of 16 - 31 October 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Despite an increased risk of cardiovascular disease (CVD) and diabetes, compliance with diabetes screening guideline in rheumatoid arthritis (RA) remains suboptimal, with little difference compared to the general population, according to a recent study.
Rheumatoid arthritis remission may be sustained following abatacept tapering, particularly in patients with shorter disease duration and long sustained remission, according to a study. Furthermore, ultrasound is a useful tool to identify disease activity flare.
Treatment with tumour necrosis factor inhibitor (TNFi) does not carry a heightened risk of cancer recurrence in patients with rheumatoid arthritis (RA) and a history of cancer, as shown in a recent study.
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Reduced caloric intake results in a significant improvement in glucose metabolism and body-fat composition, including liver-fat content, according to a study. Changes in ferritin levels appear to mediate the striking reduction in liver fat.